Allergy Department Fundación Jiménez Díaz and CIBER de Enfermedades Respiratorias (CIBERES, Institute Carlos III, Ministry of Economy and Competetiveness), Madrid, Spain.
Curr Opin Allergy Clin Immunol. 2013 Dec;13(6):646-50. doi: 10.1097/ACI.0b013e328364f4c6.
To describe the recent insights of how molecular diagnosis can be useful to improve indication and selection of suitable allergens for specific immunotherapy and to increase its safety.
As specific allergen immunotherapy is allergen-specific, the identification of the disease-eliciting allergen is a prerequisite for accurate prescription of anti-allergic treatment. In areas of complex sensitization to aeroallergens or in hymenoptera venom allergy, the use of molecular diagnosis has demonstrated that it may change indication and selection of allergens for immunotherapy in a large proportion of patients when compared with the use of skin prick testing and/or specific IgE determination with commercial extracts. These changes in the prescription of immunotherapy after using molecular diagnosis have been demonstrated to be cost-effective in some scenarios. Some patterns of sensitization to grass or olive pollen allergens may identify patients with higher risk of adverse reaction during immunotherapy.
Molecular diagnosis, together with other tools and patients' clinical history, can help clinicians better select the most appropriate patients and allergens for specific immunotherapy and, in some cases, predict the risk of adverse reactions.
描述分子诊断如何有助于提高特定免疫治疗的适应证和变应原选择,并提高其安全性。
由于特异性变应原免疫治疗是变应原特异性的,因此确定致病变应原是准确开出抗过敏治疗处方的前提。在对气传变应原复杂致敏或在蜂毒液过敏的情况下,与使用皮肤点刺试验和/或商业提取物的特异性 IgE 测定相比,分子诊断的使用表明,它可能会改变很大一部分患者免疫治疗的变应原适应证和选择。在使用分子诊断后,免疫治疗处方的这些改变在某些情况下具有成本效益。草或橄榄花粉变应原致敏的某些模式可能会识别出免疫治疗期间发生不良反应风险较高的患者。
分子诊断与其他工具和患者的临床病史一起,可以帮助临床医生更好地选择最适合的患者和变应原进行特异性免疫治疗,并且在某些情况下可以预测不良反应的风险。